earnings
confidence high
sentiment neutral
materiality 0.85
Azenta reports Q4 FY2024 revenue $170M; plans to sell B Medical; appoints Lawrence Lin CFO
Azenta, Inc.
2024-FY EPS reported
-$3.09
revenue$656,323,000
- FY2024 combined Sample Mgmt & Multiomics organic revenue grew 4%; Q4 organic growth 5%.
- Full year Adjusted EBITDA margin expanded ~300 bps to 7.5%; FY2025 guidance: 3-5% organic revenue growth and ~300 bps margin expansion.
- Board pursuing sale of B Medical Systems segment to simplify portfolio and focus on core businesses.
- Lawrence Lin appointed CFO effective after FY2024 10-K filing; Herman Cueto to serve as advisor through Q1 FY2025.
- Completed $1.5B share repurchase program, repurchasing 30M shares through September 2024.